48P (BREGO) Regorafenib combined with modified m-GEMOX in patients with advanced biliary tract cancer (BTC): A phase II randomized trial

Assenat, Éric; Blanc, J.-F.; Benameur, M.; Gauthier, Louise; Touchefeu, Yann; Portales, Fabienne; Borg, Christophe; Fares, Nikoly T.; Mineur, Laurent; Bleuse, J.-P.; Mazard, Thibault

doi:10.1016/j.annonc.2021.08.327

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on these findings, a phase III randomized trial comparing nab-paclitaxel to placebo with gemcitabine and cisplatin is currently being conducted (SWOG S1815 trial). Other combinations such as FOLFIRINOX, NUC-1031 (activated form of gemcitabine) plus cisplatin, and gemcitabine/regorafenib were not beneficial over gemcitabine and cisplatin combination (25)(26)(27)(28).…”

Section: First Line Systemic Therapymentioning

confidence: 95%

Management of locally advanced intrahepatic cholangiocarcinoma: a narrative review

Bressler¹,

Bath²,

Manne³

et al. 2023

Chin Clin Oncol

View full text Add to dashboard Cite

Background: Intrahepatic cholangiocarcinoma (ICC) is an aggressive primary hepatic malignancy, which has increased in incidence over the past decades. While surgical resection is the standard of care for patients with early-staged disease, many patients present with locally advanced and unresectable tumors. Given the importance of locoregional control and the potential for downstaging to resectability, knowledge of advances in the management of locally advanced ICC is critical for optimizing outcomes.Methods and Objective: This is a narrative review providing an up-to-date summary of the current literature regarding contemporary management of locally advanced ICC including systemic and liverdirected therapies.

show abstract

Section: First Line Systemic Therapymentioning

confidence: 95%

Management of locally advanced intrahepatic cholangiocarcinoma: a narrative review

Bressler¹,

Bath²,

Manne³

et al. 2023

Chin Clin Oncol

View full text Add to dashboard Cite

show abstract

Triple therapy in biliary tract cancers: GemOX plus immune checkpoint inhibitor in combination with lenvatinib or NGS-guided targeted therapy

Dong

Zhang

et al. 2022

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Changing Landscape of Systemic Therapy in Biliary Tract Cancer

Woods

Jakka³

et al. 2022

Cancers

View full text Add to dashboard Cite

Biliary tract cancers (BTC) are often diagnosed at advanced stages and have a grave outcome due to limited systemic options. Gemcitabine and cisplatin combination (GC) has been the first-line standard for more than a decade. Second-line chemotherapy (CT) options are limited. Targeted therapy or TT (fibroblast growth factor 2 inhibitors or FGFR2, isocitrate dehydrogenase 1 or IDH-1, and neurotrophic tyrosine receptor kinase or NTRK gene fusions inhibitors) have had reasonable success, but <5% of total BTC patients are eligible for them. The use of immune checkpoint inhibitors (ICI) such as pembrolizumab is restricted to microsatellite instability high (MSI-H) patients in the first line. The success of the TOPAZ-1 trial (GC plus durvalumab) is promising, with numerous trials underway that might soon bring targeted therapy (pemigatinib and infrigatinib) and ICI combinations (with CT or TT in microsatellite stable cancers) in the first line. Newer targets and newer agents for established targets are being investigated, and this may change the BTC management landscape in the coming years from traditional CT to individualized therapy (TT) or ICI-centered combinations. The latter group may occupy major space in BTC management due to the paucity of targetable mutations and a greater toxicity profile.

show abstract

48P (BREGO) Regorafenib combined with modified m-GEMOX in patients with advanced biliary tract cancer (BTC): A phase II randomized trial

Cited by 3 publications

References 0 publications

Management of locally advanced intrahepatic cholangiocarcinoma: a narrative review

Management of locally advanced intrahepatic cholangiocarcinoma: a narrative review

Triple therapy in biliary tract cancers: GemOX plus immune checkpoint inhibitor in combination with lenvatinib or NGS-guided targeted therapy

Changing Landscape of Systemic Therapy in Biliary Tract Cancer

Contact Info

Product

Resources

About